Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 6 of 8 for:    aducanumab | Alzheimer Disease

Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease (PROPEL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02434718
Recruitment Status : Completed
First Posted : May 5, 2015
Last Update Posted : April 10, 2017
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 9, 2016
Actual Study Completion Date : December 9, 2016